title: WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma.
abstract: Tumor-specific immunotherapy with a Wilms' tumor 1 (WT1) peptide has been on clinical trial for leukemia, myelodysplastic syndrome, breast and lung cancers and is producing promising results. In this study, we treated three patients with renal cell carcinoma with an anchor modified, HLA-A*2402 binding WT1 peptide which was emulsified in Freund's incomplete adjuvant. In two patients tumor growth was suppressed and clinical response was evaluated as stable disease by the RECIST criteria after 3 months of weekly immunizations. Notably, development of new metastases has stopped in these patients for a prolonged period. No deleterious side effects were observed. Peptide-specific T cells were expanded in PBMCs of the patients and a substantial fraction of them bore the surface phenotype consistent with a CD8+ cytotoxic effector population. Although established tumors did not regress further, considering the component of the vaccine, i.e. peptide alone, the stabilization effect suggested the potential of WT1 peptide to develop into a more effective vaccine. To our knowledge, this is the first report of WT1 immunotherapy for renal cell carcinoma. Hopefully, the results will stimulate more extensive clinical studies.
authors.affiliation: Department of Immunology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Iiyama
authors.forename: Keiko
authors.initials: K
authors.lastname: Udaka
authors.forename: Sachihiko
authors.initials: S
authors.lastname: Takeda
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Takeuchi
authors.forename: Yoshihiro C
authors.initials: YC
authors.lastname: Adachi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Ohtsuki
authors.forename: Akihiro
authors.initials: A
authors.lastname: Tsuboi
authors.forename: Shin-ichi
authors.initials: S
authors.lastname: Nakatsuka
authors.forename: Olga A
authors.initials: OA
authors.lastname: Elisseeva
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Oji
authors.forename: Manabu
authors.initials: M
authors.lastname: Kawakami
authors.forename: Hiroko
authors.initials: H
authors.lastname: Nakajima
authors.forename: Sumiyuki
authors.initials: S
authors.lastname: Nishida
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Shirakata
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Oka
authors.forename: Taro
authors.initials: T
authors.lastname: Shuin
authors.forename: Haruo
authors.initials: H
authors.lastname: Sugiyama
mesh_terms: D000368:Aged; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D018797:Cell Cycle Proteins; D005260:Female; D015234:HLA-A Antigens / Q000276:immunology; D059871:HLA-A24 Antigen; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D008297:Male; D009362:Neoplasm Metastasis / Q000276:immunology; D009687:Nuclear Proteins / Q000276:immunology*; D000072260:RNA Splicing Factors; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: D019496:Cancer Vaccines; D018797:Cell Cycle Proteins; D015234:HLA-A Antigens; C438506:HLA-A*24:02 antigen; D059871:HLA-A24 Antigen; D009687:Nuclear Proteins; D000072260:RNA Splicing Factors; C419554:WTAP protein, human